Prospective evaluation of early Abciximab and primary percutaneous intervention for patients with ST elevation myocardial infarction complicated by cardiogenic shock: Results of the REO-SHOCK trial

Journal of Invasive Cardiology

Volumn 15, Issue 7, 2003, Pages 385-389

  Zeymer, Uwe ^h   Tebbe, Ulrich ^a   Weber, Michael ^b   Vöhringer, Hans F ^c   Jaksch, Rainer ^d   Bischoff, Karl Otto ^e   Toepel, Wolfgang ^f   Marsalek, Parvaneh ^g   Horn, Stefan ⁱ   Neuhaus, Karl Ludwig ⁱ  

^a KLINIKUM LIPPE DETMOLD   (Germany)

^b Amper Kliniken   (Germany)

^c DRK Kliniken   (Germany)

^d St Vincenz Krankenhaus   (Germany)

^e Medizinische Klinik   (Germany)

^f Med Klinik II   (Germany)

^g LILLY DEUTSCHLAND GMBH   (Germany)

^h KLINIKUM LUDWIGSHAFEN   (Germany)

ⁱ NONE

Author keywords

Acute myocardial infarction; Percutaneous coronary intervention; Primary angioplasty; Revascularization

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; HEPARIN;

ACUTE DISEASE; ADULT; AGE; AGED; ARTICLE; BIOSAFETY; BLEEDING; BLOOD CLOT LYSIS; BOLUS INJECTION; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY STENT; EVALUATION; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MALE; MORTALITY; PATIENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROSPECTIVE STUDY; ST SEGMENT ELEVATION; STROKE; THROMBOSIS; TREATMENT OUTCOME; VASCULAR PATENCY;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; STENTS;

EID: 0038502011     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective. N Engl J Med 1991;325:1117-1122.
2. Hasdai D, Holmes DR, Topol EJ, et al. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III Conclusion. Eur Heart J 1999;20:128-135.
3. Hasdai D, Topol EJ, Califf RM, et al. Cardiogenic shock complicating acute coronary syndromes. Lancet 2000;356:749-756.
4. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986;1:397-402.
5. Lee I, Bates ER, Pitt B, et al. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988;78:1345-1351.
6. Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Circulation 1995;91:873-881.
7. Zeymer U, Vogt A, Niederer W, et al., for the ALKK Study Group. Primary PTCA with and without stent implantation in 671 patients with acute myocardial infarction complicated by cardiogenic shock. Results of the ALKK Primary PTCA Registry. J Am Coll Cardiol 2000;35(Suppl A):363A.
8. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999;341:625-634.
9. Hochman JS, Sleeper LA, White HD. One-year survival following early revascularization for cardiogenic shock. JAMA 2001;285:190-192.
10. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701.
11. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
12. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-741.
13. Azar RR, McKay RG, Thompson PD, et al. Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes. J Am Coll Cardiol 1998;32:1996-2002.
14. Giri S, Mitchel J, Azar RR, et al. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002;89:126-131.
15. Chan AW, Chew DP, Bhatt DL, et al. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2002;89:132-136.
16. Antoniucci D, Valenti R, Migliorini A, et al. Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol 2002;90:353-357.
17. Topol EJ. Towards a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence. Circulation 1998;97:211-218.
18. Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction (SMASH). Eur Heart J 1999;20:1030-1038.